INS and Hypoglycemia: There are several other factors associated with Gla‐300 treatment that may predispose to better persistence, including flexibility of injection timing, single daily injections and lower injections volumes.25 Our study reinforces data from the EDITION trial series showing that Gla‐300 is associated with less hypoglycaemia than other basal insulins.6, 7, 8, 9 Patients in this cohort who switched to Gla‐300 were less likely to experience hypoglycaemia both at 3‐ and at 6‐month follow‐up compared with those who switched to other basal insulins.